ADM (NYSE: ADM), a global leader in innovative solutions from nature, today announced that Fibersol®, a premier line of soluble prebiotic fibers, has received approval from the Therapeutic Goods Administration (TGA), part of the Australian Department of Health, for use as an active ingredient in biologicals, listed medicines, and prescription medicines. The approval expands Fibersol®’s role beyond conventional food and beverage applications into dietary supplements and other regulated health product categories. 

“Securing TGA approval for Fibersol® marks a significant development for ADM,” said Helen Hu, president of health & wellness APAC at ADM. “It allows our customers to highlight Fibersol®’s clinically supported health benefits on packaging, providing clear value in a category where consumer trust is essential. In today’s dynamic health and wellness market, regulatory approvals are more than a requirement; they are a mark of credibility. With this approval, ADM continues to deliver science-backed solutions that give brands a competitive edge and consumers greater confidence in their choices.” 

Backed by more than 100 scientific publications, Fibersol® has been extensively researched, demonstrating its potential across a wide range of health indications. Clinically documented results show that Fibersol®: 

• Promotes the growth of beneficial gut bacteria^1,2 
• Supports a healthy gut microbiota and overall digestive health^1,2 
• Nourishes intestinal flora and maintains a balanced intestinal environment² 
• May delay hunger and support normal production of GLP-1 and peptide yy³ 
• Consumption of Fibersol-2™ is associated with a reduction in the uptake of sugars from dietary carbohydrates and in the absorption of dietary triglycerides^4,5 

In addition to its clinically supported benefits, Fibersol® is well-tolerated and versatile⁶, with stability observed under heat, acid, shear, and freeze/thaw conditions. Its neutral taste profile makes it easy to incorporate across foods, beverages, and dietary supplements, enabling brands to deliver enjoyable, gut-friendly products without compromising on taste or texture. 

The prebiotics market in Australia is projected to grow at a CAGR of 17.6% between 2024 and 20307, driven by rising consumer focus on digestive health. Nearly 40% of Australian consumers have taken steps to improve their digestive health in the past year, of which more than one-third (39%) are choosing supplements and vitamins to support this goal⁸, highlighting a shift toward targeted, science-backed solutions. 

This growing interest in digestive health aligns with the expanding role of prebiotic fibers in supplements and functional products. ADM’s latest approval adds to its portfolio of TGA-recognized ingredients, following DE111™ in 2024, and underscores Fibersol®’s strong clinical foundation. 

For more information about Fibersol® and ADM’s specialty health solutions, please visit https://www.adm-asia.com/en-us/products-services/human-nutrition/products/specialty-health-solutions/. 

About ADM 

ADM unlocks the power of nature to enrich the quality of life. We’re an essential global agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. We’re a premier human and animal nutrition provider, offering one of the industry’s broadest portfolios of ingredients and solutions from nature. We’re a trailblazer in health and well-being, with an industry-leading range of products for consumers looking for new ways to live healthier lives. We’re a cutting-edge innovator, guiding the way to a future of new bio-based consumer and industrial solutions. And we’re leading in business-driven sustainability efforts that support a strong agricultural sector, resilient supply chains, and a vast and growing bioeconomy. Around the globe, our expertise and innovation are meeting critical needs from harvest to home. Learn more at www.adm.com. 

¹ Fahey, GC. J. Nutr., 130, 1267-1273 

² Burns A. (2018). Nutrition Research, 60, 33-42 

³ Ye, Z. (2015). Nutritional Research, 35, 393-400 

⁴ Yuasa, M. et al. (2004). Jpn Innov Food Ingred Res, 7:83-93 

⁵ Tanaka, T. et al. (2011), Jpn Pharmocol Ther., 339: 813-821 Randomized double-blind crossover study (73 subjects) on carbonated beverage with 5g resistant maltodextrin taken with high fat meal (42g fat) showed significantly lower postprandial serum triglycerides compared to placebo 

⁶ Kishimoto, Y., et al. (2013) J. Nutr. Sci. Vitaminol (Tokyo) 59(4):352-7 

⁷ Grand View Research, Australia Prebiotics Market Size & Outlook, 2023-2030 

⁸ ADM Outside Voice Lifestyle Survey 2025